General Information of Drug Transporter (DT)
DT ID	DTD0109 Transporter Info
Gene Name	SLC16A5
Protein Name	Monocarboxylate transporter 6
Gene ID	9121
UniProt ID	O15375
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs4788863
Site of GPD	chr17:75093757 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.3746/1876 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Cisplatin	Drug Info	Testicular Neoplasm	Correlated with the decreased likelihood of ototoxicity in patients (compare with allele C)		[ 1]
Cisplatin	N.A.	Ototoxicity	Allele T is associated with decreased likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele C.		[ 1]
Cisplatin	N.A.	Neoplasms	Allele T is associated with decreased likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele C.		[ 1]
Cisplatin	N.A.	Testicular Neoplasms	Allele T is associated with decreased likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele C.		[ 1]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Cisplatin	N.A.	Ototoxicity	Allele C is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele T.		[ 2]
Cisplatin	N.A.	Neoplasms	Allele C is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele T.		[ 2]
Cisplatin	N.A.	Testicular Neoplasms	Allele C is not associated with risk of Ototoxicity due to cisplatin in children with Neoplasms as compared to allele T.		[ 2]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Cisplatin	N.A.	Neoplasms	Patients with the CC genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CT or TT genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.		[ 1]
Cisplatin	N.A.	Ototoxicity	Patients with the CC genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CT or TT genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.		[ 1]
Cisplatin	N.A.	Testicular Neoplasms	Patients with the CC genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CT or TT genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.		[ 1]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Cisplatin	N.A.	Neoplasms	Patients with the CT genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the TT genotype, and a decreased risk as compared to patients with the CC genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.		[ 1]
Cisplatin	N.A.	Ototoxicity	Patients with the CT genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the TT genotype, and a decreased risk as compared to patients with the CC genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.		[ 1]
Cisplatin	N.A.	Testicular Neoplasms	Patients with the CT genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the TT genotype, and a decreased risk as compared to patients with the CC genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.		[ 1]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Cisplatin	N.A.	Neoplasms	Patients with the TT genotype and cancer may have a decreased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CC or CT genotypes. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.		[ 1]
Cisplatin	N.A.	Ototoxicity	Patients with the TT genotype and cancer may have a decreased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CC or CT genotypes. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.		[ 1]
Cisplatin	N.A.	Testicular Neoplasms	Patients with the TT genotype and cancer may have a decreased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CC or CT genotypes. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.		[ 1]
References
1	Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. JAMA Oncol. 2017 Nov 1;3(11):1558-1562.
2	Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. Pharmacogenomics J. 2020 Apr;20(2):294-305.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.